FDA Approves Long-Acting HIV Prevention Injection
TL;DR Summary
The FDA has approved Gilead Sciences' twice-yearly injection of lenacapavir, branded Yeztugo, as a highly effective HIV prevention method, offering a new, discreet alternative to existing PrEP options and potentially transforming HIV prevention efforts worldwide.
- FDA approves twice-a-year injection for HIV prevention CNN
- Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection Gilead Sciences
- Regulators Approve Lenacapavir for H.I.V. Prevention The New York Times
- FDA approves powerful HIV prevention drug: What to know about Yeztugo NBC News
- Gilead’s CEO on the approval of a powerful new drug to prevent HIV STAT
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
8 min
vs 8 min read
Condensed
98%
1,595 → 35 words
Want the full story? Read the original article
Read on CNN